FMP
Salarius Pharmaceuticals, Inc.
SLRX
NASDAQ
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.
2.69 USD
0.07 (2.6%)
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
3.47M
5.23M
1.84M
-
-
-
-
-
-
-
-
51.03
-64.84
-100
-
-28.45
-28.45
-28.45
-28.45
-11.58M
-10.31M
-10.2M
-17.6M
-12.85M
-
-
-
-
-
-334.2
-197.03
-554.29
100
100
-20
-20
-20
-20
-
-2.6k
-
-1.5M
-3
-
-
-
-
-
-
-0.05
-
100
100
-0.01
-0.01
-0.01
-0.01
-11.58M
-10.31M
-10.2M
-19.1M
-12.85M
-
-
-
-
-